Cookie Consent by

Publicaciones científicas

Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab

01-feb-2007 | Revista: Clinical and Translational Oncology

M. González Cao, S. Viteri, C. Garrán, Y. Nieto, J. Aristu, M. Ponz and S. Martín Algarra

Oncology Department, Clínica Universitaria de Navarra, Pamplona, Spain

We report here a taxol–bevacizumab-responsive metastatic melanoma case.

Although the patient had been heavily pretreated for two years, she did not show any stabilisation or objective response of her disease. After treatment with taxol and bevacizumab combination an impressive response was obtained.

CITA DEL ARTÍCULO  Clin Transl Oncol. 2007 Feb;9(2):119-20